Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_assertion type Assertion NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_head.
- NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_assertion description "[TZDs including pioglitazone, rosiglitazone and troglitazone, by activating PPAR-? have shown pleiotropic effects in reducing vascular risk factors and atherosclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_provenance.
- NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_assertion evidence source_evidence_literature NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_provenance.
- NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_assertion SIO_000772 25521362 NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_provenance.
- NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_assertion wasDerivedFrom befree-2016 NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_provenance.
- NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_assertion wasGeneratedBy ECO_0000203 NP1249175.RAJ3O4EKNzwWJoBB4oCk9f6VCdl5zXnw5VfPPg82VelB0130_provenance.